Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04721262 · ClinicalTrials.gov registry record
Ferumoxytol Enhanced Hyperfine Low Field Strength MRI
A clinical trial, sponsored by University of Pennsylvania.
- Completed
- Registry status
- 2
- Enrollment target
NCT04721262: Completed study, sponsored by University of Pennsylvania.
NCT04721262 is a clinical trial that has completed, run by University of Pennsylvania. The registered enrollment target is 2 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04721262 has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- 2 participants
- Enrollment target
Study Summary
The purpose of this pilot study is to evaluate the feasibility of using Ferumoxytol as a contrast agent on a low field strength, portable magnetic resonance imaging (MRI) system. Participants receiving Ferumoxytol as part of routine clinical care for iron deficiency anemia will be recruited and scanned on the Hyperfine MRI system before and after their clinically scheduled intravenous infusion. Resultant images will be compared to assess signal intensity changes generated by the presence of Feromoxytol.
Interventions
- DEVICE Hyperfine Portable MRI
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-11-09 |
| Est. Completion | 2022-08-29 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04721262
The ClinicalTrials.gov registry entry for NCT04721262 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Hyperfine Portable MRI is the first listed.
NCT04721262 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04721262 about?
NCT04721262 is a clinical study titled "Ferumoxytol Enhanced Hyperfine Low Field Strength MRI". The purpose of this pilot study is to evaluate the feasibility of using Ferumoxytol as a contrast agent on a low field strength, portable magnetic resonance imaging (MRI) system. Participants receiving Ferumoxytol as part of routine clinical care for iron deficiency anemia will be recruited and scan...
What is the current status of trial NCT04721262?
This trial is currently completed. The enrollment target is 2 participants. The study started on 2020-11-09. Estimated completion is 2022-08-29.
What interventions are being tested in trial NCT04721262?
The interventions under investigation include: Hyperfine Portable MRI (DEVICE).
Who is sponsoring clinical trial NCT04721262?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.